Indivior Pharmaceuticals (FRA:E7P) Long-Term Debt: €423 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:E7P Indivior Pharmaceuticals Inc FRA:E7P
71 GF Score
Price €32.80
GF Value €21.12
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Indivior Pharmaceuticals Long-Term Debt?

Indivior Pharmaceuticals FRA:E7P -1.20% 71 Long-Term Debt is €423 Mil as of Jun. 2026. GuruFocus rates FRA:E7P with a GF Score™ of 71/100 and a GF Value™ of €21.12 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Indivior Pharmaceuticals's Long-Term Debt for the quarter that ended in Jun. 2026 was €423 Mil.

Indivior Pharmaceuticals's quarterly Long-Term Debt increased from Dec. 2025 (€248 Mil) to Mar. 2026 (€420 Mil) and increased from Mar. 2026 (€420 Mil) to Jun. 2026 (€423 Mil).

Indivior Pharmaceuticals's annual Long-Term Debt increased from Dec. 2023 (€216 Mil) to Dec. 2024 (€301 Mil) but then declined from Dec. 2024 (€301 Mil) to Dec. 2025 (€248 Mil).

Indivior Pharmaceuticals  (FRA:E7P) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Indivior Pharmaceuticals Long-Term Debt Related Terms

Indivior Pharmaceuticals Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Indivior Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indivior Pharmaceuticals Long-Term Debt Chart

Indivior Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 211.52 223.73 216.41 300.83 247.66

Indivior Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 267.04 259.01 247.66 420.39 422.72
FRA:E7P
71GF Score
Indivior Pharmaceuticals Inc FRA:E7P
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €423 Mil mean?
Indivior Pharmaceuticals (FRA:E7P) has a Long-Term Debt of €423 Mil as of Jun. 2026.
Is Indivior Pharmaceuticals' Long-Term Debt too high?
Indivior Pharmaceuticals' current Long-Term Debt is €423 Mil. Overall, Indivior Pharmaceuticals has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' Long-Term Debt compare to KNSA and AMRX?
Indivior Pharmaceuticals' Long-Term Debt of €423 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Indivior Pharmaceuticals's current Long-Term Debt is €423 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (FRA:E7P) is currently considered Significantly Overvalued. The stock's GF Value™ is €21.12, compared to a current price of €32.80 — trading 55.3% above its estimated fair value. The current Long-Term Debt is €423 Mil. Indivior Pharmaceuticals' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Indivior Pharmaceuticals (FRA:E7P), the current Long-Term Debt is €423 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indivior Pharmaceuticals (FRA:E7P) Overvalued in 2026?

Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued. The current stock price of €32.80 is trading 55.3% above its estimated GF Value™ of €21.12. GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:E7P:

  • Long-Term Debt: €423 Mil
  • GF Value™: €21.12 vs. price of €32.80 (55.3% above fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the FRA:E7P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Indivior Pharmaceuticals Business Description

Other Exchanges INDV:USA
Address 10710 Midlothian Turnpike, Suite 125, North Chesterfield, Richmond, VA, USA, 23235
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
71GF Score

Get the complete analysis for FRA:E7P

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.80
Price
€21.12
GF Value